TY - JOUR
T1 - Advances in Lentivirus Purification
AU - Moreira, Ana Sofia
AU - Cavaco, David Guia
AU - Faria, Tiago Q.
AU - Alves, Paula M.
AU - Carrondo, Manuel J. T.
AU - Peixoto, Cristina
N1 - Funding Information:
The authors would like to acknowledge funding from the iNOVA4Health Research Unit (LISBOA‐01‐0145‐FEDER‐007344), which is co‐funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência e do Ensino Superior (FCT/MCES). Funds by FEDER under the PT2020 Partnership Agreement is also acknowledged. The authors Ana Sofia Moreira and Tiago Q. Faria acknowledge FCT/MCES for the Ph.D. fellowship PD/BD/135501/2018 and the project PTDC/EQU‐EPQ/29306/2017, respectively.
Funding Information:
The authors would like to acknowledge funding from the iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344), which is co-funded by Funda??o para a Ci?ncia e Tecnologia/Minist?rio da Ci?ncia e do Ensino Superior (FCT/MCES). Funds by FEDER under the PT2020 Partnership Agreement is also acknowledged. The authors Ana Sofia Moreira and Tiago Q. Faria acknowledge FCT/MCES for the Ph.D. fellowship PD/BD/135501/2018 and the project PTDC/EQU-EPQ/29306/2017, respectively.
Publisher Copyright:
© 2020 The Authors. Biotechnology Journal published by Wiley-VCH GmbH
PY - 2021/1
Y1 - 2021/1
N2 - Lentiviral vectors (LVs) have been increasingly used as a tool for gene and cell therapies since they can stably integrate the genome in dividing and nondividing cells. LV production and purification processes have evolved substantially over the last decades. However, the increasing demands for higher quantities with more restrictive purity requirements are stimulating the development of novel materials and strategies to supply the market with LV in a cost-effective manner. A detailed review of each downstream process unit operation is performed, limitations, strengths, and potential outcomes being covered. Currently, the majority of large-scale LV manufacturing processes are still based on adherent cell culture, although it is known that the industry is migrating fast to suspension cultures. Regarding the purification strategy, it consists of batch chromatography and membrane technology. Nevertheless, new solutions are being created to improve the current production schemes and expand its clinical use.
AB - Lentiviral vectors (LVs) have been increasingly used as a tool for gene and cell therapies since they can stably integrate the genome in dividing and nondividing cells. LV production and purification processes have evolved substantially over the last decades. However, the increasing demands for higher quantities with more restrictive purity requirements are stimulating the development of novel materials and strategies to supply the market with LV in a cost-effective manner. A detailed review of each downstream process unit operation is performed, limitations, strengths, and potential outcomes being covered. Currently, the majority of large-scale LV manufacturing processes are still based on adherent cell culture, although it is known that the industry is migrating fast to suspension cultures. Regarding the purification strategy, it consists of batch chromatography and membrane technology. Nevertheless, new solutions are being created to improve the current production schemes and expand its clinical use.
KW - bioseparation
KW - chromatography
KW - downstream processing
KW - lentiviral vectors
UR - http://www.scopus.com/inward/record.url?scp=85097279265&partnerID=8YFLogxK
U2 - 10.1002/biot.202000019
DO - 10.1002/biot.202000019
M3 - Review article
C2 - 33089626
AN - SCOPUS:85097279265
SN - 1860-6768
VL - 16
JO - Biotechnology Journal
JF - Biotechnology Journal
IS - 1
M1 - 2000019
ER -